{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T23:00:12Z","timestamp":1784934012806,"version":"3.55.0"},"reference-count":25,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["J Prim Care Community Health"],"published-print":{"date-parts":[[2023,1]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Hepatitis C virus (HCV) infection is common among persons who inject drugs (PWID), mostly due to needle sharing. The number of new cases in PWID are steadily increasing despite the availability of effective treatments. The objective of this model is to increase uptake and compliance with HCV treatment. We developed a model to treat HCV and opioid use disorder simultaneously in a methadone maintenance program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Patients were screened on site for HCV at admission and then annually. Once HCV was positive, the genotypes and fibrosis scores were identified. Patients were enrolled into the treatment program after obtaining written consent. Patients either self-administered the medications at home or utilized a directly observed treatment (DOT). The sustained virologic response (SVR) was tested at 12\u2009weeks posttreatment. We conducted a retrospective review of patients who received treatment and reviewed the demographic data, co-infections, medication administration, and SVR results at the end of study period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>One hundred ninety patients were identified as Hepatitis C positive. 88.9% (169 patients) received HCV treatment during the study period. 62.7% (106 patients) were male and 37.3% were female (63 patients). 62.7% of them (106 patients) completed HCV treatment by the end of study period. Out of them, 96.2% (102 patients) achieved SVR. 68.9% (73 patients) utilized DOT for medication administration.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>Our model successfully treated HCV in our patient population, who are otherwise deprived of resources and access to health care. Replicating this model is a potential strategy to reduce the disease burden and break the transmission cycle of HCV.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/21501319231164884","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T02:10:49Z","timestamp":1680487849000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Hepatitis C Treatment in Persons Who Inject Drugs in a Medication Assisted Treatment Program: A Retrospective Review of an Integrated Model"],"prefix":"10.1177","volume":"14","author":[{"given":"Raymond","family":"Bobb","sequence":"first","affiliation":[{"name":"Merakey Parkside Recovery, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9923-8638","authenticated-orcid":false,"given":"Srikrishna Varun","family":"Malayala","sequence":"additional","affiliation":[{"name":"Merakey Parkside Recovery, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebun","family":"Ajayi","sequence":"additional","affiliation":[{"name":"Merakey Parkside Recovery, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aliya","family":"Wimbush","sequence":"additional","affiliation":[{"name":"Merakey Parkside Recovery, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Bobb","sequence":"additional","affiliation":[{"name":"Merakey Parkside Recovery, Philadelphia, PA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2023,4,2]]},"reference":[{"key":"bibr1-21501319231164884","unstructured":"Centers for Disease Control and Prevention. Viral hepatitis surveillance\u2014United States, 2019. US Department of Health and Human Services, Centers for Disease Control and Prevention. 2020. Accessed January 4, 2023. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2019surveillance\/index.htm"},{"key":"bibr2-21501319231164884","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2019.04.035"},{"key":"bibr3-21501319231164884","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30297"},{"key":"bibr4-21501319231164884","doi-asserted-by":"publisher","DOI":"10.1186\/s13011-020-00306-1"},{"key":"bibr5-21501319231164884","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz659"},{"key":"bibr6-21501319231164884","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000975"},{"key":"bibr7-21501319231164884","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.13989"},{"key":"bibr8-21501319231164884","doi-asserted-by":"publisher","DOI":"10.1001\/jamapediatrics.2019.1750"},{"key":"bibr9-21501319231164884","doi-asserted-by":"publisher","DOI":"10.1111\/rssa.12411"},{"key":"bibr10-21501319231164884","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06201-6"},{"key":"bibr11-21501319231164884","unstructured":"American Association for the Study of Liver Diseases. Initial treatment of adults with HCV infection. Accessed January 14, 2022. https:\/\/www.hcvguidelines.org\/treatment-%20naive"},{"issue":"8","key":"bibr12-21501319231164884","first-page":"e28160","volume":"14","author":"Malayala SV","year":"2022","journal-title":"Cureus"},{"issue":"5","key":"bibr13-21501319231164884","first-page":"305","volume":"14","author":"Pockros PJ.","year":"2018","journal-title":"Gastroenterol Hepatol"},{"key":"bibr14-21501319231164884","doi-asserted-by":"publisher","DOI":"10.3390\/molecules26010039"},{"key":"bibr15-21501319231164884","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22759"},{"key":"bibr16-21501319231164884","doi-asserted-by":"publisher","DOI":"10.1097\/01.NAJ.0000652004.90791.e9"},{"issue":"10","key":"bibr17-21501319231164884","first-page":"664","volume":"95","author":"Sokol R.","year":"2017","journal-title":"Am Fam Physician"},{"key":"bibr18-21501319231164884","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S171338"},{"key":"bibr19-21501319231164884","unstructured":"Centers for Disease Control and Prevention, National Center for Health Statistics. Multiple cause of death 1999\u20132018. Data are from the multiple cause of death files, 1999\u20132018, as compiled from data provided by the 57 vital statistics jurisdictions through the Vital Statistics Cooperative Program. 2020. Accessed January 22, 2023. http:\/\/wonder.cdc.gov\/mcd-icd10.html"},{"key":"bibr20-21501319231164884","unstructured":"Centers for Disease Control and Prevention. Viral hepatitis surveillance\u2014United States, 2018. US Department of Health and Human Services, Centers for Disease Control and Prevention. 2020. Accessed January 22, 2023. https:\/\/www.cdc.gov\/hepatitis\/statistics\/2018surveillance\/pdfs\/2018HepSurveillanceRpt.pdf"},{"key":"bibr21-21501319231164884","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2022.107136"},{"key":"bibr22-21501319231164884","doi-asserted-by":"publisher","DOI":"10.14218\/JCTH.2018.00016"},{"key":"bibr23-21501319231164884","unstructured":"American Association for the Study of Liver Diseases. Patients with HIV\/HCV coinfection. Accessed January 14, 2023. https:\/\/www.hcvguidelines.org\/unique-populations\/hiv-hcv"},{"key":"bibr24-21501319231164884","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(21)00397-6"},{"issue":"1","key":"bibr25-21501319231164884","first-page":"79","volume":"6","author":"Axley P","year":"2018","journal-title":"J Clin Transl Hepatol"}],"container-title":["Journal of Primary Care &amp; Community Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21501319231164884","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/21501319231164884","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/21501319231164884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:23:56Z","timestamp":1777508636000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/21501319231164884"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":25,"alternative-id":["10.1177\/21501319231164884"],"URL":"https:\/\/doi.org\/10.1177\/21501319231164884","relation":{},"ISSN":["2150-1319","2150-1327"],"issn-type":[{"value":"2150-1319","type":"print"},{"value":"2150-1327","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1]]},"article-number":"21501319231164884"}}